Edgewise Therapeutics
EWTX
78 hedge funds and large institutions have $406M invested in Edgewise Therapeutics in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 28 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
8% more funds holding
Funds holding: 72 → 78 (+6)
6.2% less ownership
Funds ownership: 109% → 102.8% (-6.2%)
23% less capital invested
Capital invested by funds: $524M → $406M (-$118M)
36% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 28
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.11M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.56M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.22M |
| 4 |
Janus Henderson Group
London,
|
+$1.33M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$25.4M |
| 2 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$6.43M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$6.3M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$2.93M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$769K |
EWTX Hedge Fund Activity: Q2 2022 in Review
78 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2022, worth a combined $406M — down 23% from $524M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new EWTX positions and 10 closed out — a net gain of 7 holders — while 18 added to existing stakes and 28 trimmed.
The largest buyer was Woodline Partners, adding an estimated $3.11M. The largest seller was RA Capital Management, exiting entirely with an estimated $25.4M sold.
- 78 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2022, up from 72 in Q1 2022.
- Funds reported $406M of Edgewise Therapeutics stock for Q2 2022, down 23% quarter-over-quarter.
- 17 funds opened new Edgewise Therapeutics positions in Q2 2022 and 10 closed out, a net change of +7 holders.
- The largest Edgewise Therapeutics buyer in Q2 2022 was Woodline Partners, an estimated $3.11M added.
- The largest Edgewise Therapeutics seller in Q2 2022 was RA Capital Management, an estimated $25.4M sold.
Based on aggregated 13F filings for Q2 2022.